Juvaris gets infusion for infectious disease vaccines

Juvaris BioTherapeutics, a Burlingame, Calif.-based developer of vaccines to treat infectious diseases, announced that it raised financing toward its targeted $25 million second round of funding from SV Life Sciences and Kleiner Perkins Caufield & Byers. The company wouldn’t put a finer point on the amount, mostly because it is open to further investments in the round.

The money will give Juvaris a two-year runway to improve the immune responses caused by its vaccines. Right now, it is working on preventative treatments for the flu, as well as the herpes simplex virus type 2. It previously brought in $12 million in a first round of funding from Kleiner Perkins.

Next Story:
Previous Story:

About the Author,

Camille was the lead writer for GreenBeat until August 2010. To reach VentureBeat's current writers, email tips@venturebeat.com.

blog comments powered by Disqus